Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

January 31, 2024

https://www.globenewswire.com/news-release/2024/01/31/2821064/0/en/Phio-Pharmaceuticals-Announces-Data-Showing-INTASYL-May-Result-in-More-Effective-Cell-Therapy-for-Hematological-Malignancies.html

—New preclinical data to be presented at Immunotherapy Conference in Germany

MARLBOROUGH, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that new preclinical data demonstrating the potential of INTASYL self-delivering siRNA targeting Cbl-b improves natural killer (NK) cell activity for adoptive cell therapy and may result in a more effective cell therapy for hematological malignancies will be presented at the 10th Immunotherapy of Cancer Conference (ITOC10), which will be held in Munich, Germany from March 21-23, 2024.

Read more at globenewswire.com

Related news for (PHIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.